A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: mistake (35), fault (22), slip (31)

HSCTCyclophosphamide Priming (1500)

Description
Chemotherapy Protocol Haematopoietic Stem Cell Transplant (Autograft) CYCLOPHOSPHAMIDE PRIMING (1500mg/m2) Regimen • Haematopoietic Stem Cell Transplant (HSCT)- Cyclophosphamide Priming (1500mg/m2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTCyclophosphamide-Priming-1500.pdf

DA_3+8_CADD

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA Ambulatory Regimen AmB - DA (3+8) CADD–Cytarabine-Daunorubicin Regimen • Acute Myeloid Leukaemia – AmB - DA (3
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8-CADD.pdf

Paclitaxel (7 day)

Description
Chemotherapy Protocol BREAST CANCER PACLITAXEL (7 day) Regimen • Breast Cancer – Paclitaxel (7 day) Indication • Treatment of locally advanced or metastatic breast
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Paclitaxel-7-day.pdf

Paclitaxel (7 day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER PACLITAXEL (7 day) Regimen • Ovary – Paclitaxel (7 day) Indication • Second or subsequent line treatment of platinum refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Paclitaxel-7-day.pdf

Liposomal doxorubicin

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER LIPOSOMAL DOXORUBICIN (Caelyx) Please note this protocol is based on information for the use of the Caelyx
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Liposomaldoxorubicin.pdf

Irinotecan Mitomycin

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER IRINOTECAN-MITOMYCIN Regimen Ovary-Irinotecan-Mitomycin Indication Platinum refractory clear cell or mucinous ovarian cancer Recurrent platinum
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/IrinotecanMitomycin.pdf

Cisplatin Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (Oral) Regimen Ovary-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CisplatinEtoposidePO.pdf

Bevacizumab (15mgkg)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15) This protocol may require funding Regimen Ovary-Bevacizumab (15) Indication Recurrent platinum sensitive ovarian, peritoneal
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkg.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Uterine-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Topotecan

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-TOPOTECAN (intravenous) Regimen Cervix-Cisplatin-Topotecan IV Indication Recurrent stage IVB cervical cancer in patients who
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandTopotecan.pdf
211 to 220 of 630
Previous … 20 21 22 23 24 … Next